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Pharmacologic inhibition of nitric oxide synthases
and cyclooxygenases enhances intimal hyperplasia
in balloon-injured rat carotid arteries
Jens W. Fischer, PhD,a Suzanne Hawkins,b and Alexander W. Clowes, MD,b Du¨sseldorf, Germany; and
Seattle, Wash
Objective: Extensive proliferation and migration of smooth muscle cells (SMCs) contribute to development of fibromus-
cular intimal hyperplasia in response to balloon catheter–induced injury of the left carotid artery in Fischer 344 rats. The
purpose of the present study was to test the hypothesis that endogenously generated nitric oxide (NO) and prostaglandins
act synergistically to limit the extent of neointimal hyperplasia.
Methods: The left carotid artery of Fischer 344 rats was injured with a 2F balloon catheter. The following treatment was
initiated 24 hours before arterial injury, and was continued for 2 weeks: N-nitro-L-arginine (L-NA; 10 mg/kg/d, in
drinking water), indomethacin (1.5 mg/kg/d per gavage), and L-NA (10 mg/kg/d) plus indomethacin (1.5 mg/kg/d).
After application of an overdose of pentobarbital animals were formalin-fixed. Subsequently, paraffin-embedded cross
sections of the uninjured and injured carotid arteries were analyzed morphometrically. SMC proliferation was determined
by incorporation of 5-bromo-2-deoxyuridine.
Results: Two weeks after injury, L-NA caused a 1.29-fold  0.29-fold (mean  SD; n  14; P < .05) increase in the
intima-media ratio, compared with control animals, whereas indomethacin had no effect. Combined treatment with
L-NA plus indomethacin further increased intima-media ratio (1.65-fold 0.5-fold over control; n 14; P < .05). SMC
proliferation in the neointima of rats treated with L-NA and L-NA plus indomethacin was elevated. Furthermore,
neointimal cell density (nuclei per square millimeter) was reduced after combined inhibition of cyclooxygenases and NO
synthases.
Conclusion: The present results of pharmacologic NO synthase and cyclooxygenase inhibition suggest that NO and
prostaglandins are part of an endogenous growth inhibitory mechanism that synergistically suppresses intimal thicken-
ing. (J Vasc Surg 2004;40:115-22.)
Clinical Relevance: The role of cyclooxygenase-1 (COX1) and cyclooxygenase-2 (COX2) during vascular recurrent
stenosis and atherosclerosis is not clear yet. In particular, the effects of selective COX2 inhibitors on the frequency of
cardiovascular events is still controversial. It is shown here in rats that the application of a non-selective COX inhibitor
does not affect arterial stenosis. However, the concurrent inhibition of endogenous nitric oxide generation and COX1 or
COX2 causes overshooting neointimal hyperplasia. These results suggest that increased vascular stenosis can result from
administration of drugs that pharmacologically block 2 or more inhibitory pathways that normally counterbalance the
effect of promotors of neointimal hyperplasia.An important limitation of percutaneous transluminal
coronary angioplasty is recurrent stenosis during the first
months after initially successful interventions. A widely
used experimental model to study arterial restenosis is
neointimal hyperplasia, which develops in rats in response
to balloon injury of the common carotid artery. Neointimal
hyperplasia in rats is initiated by smooth muscle cell (SMC)
replication in the media,1 followed by SMC migration
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intimal SMCs for a limited time.4 After proliferation has
ceased, further expansion of the neointima is predomi-
nantly due to synthesis and accumulation of extracellular
matrix (ECM). ECM accumulation accounts for about 80%
of the intimal volume between 2 and 12 weeks after injury.5
Thus far it is not known which mechanisms or mediators
are responsible for the fact that neointimal hyperplasia
eventually stops and even regresses in the rat model.
Candidates for endogenous inhibitors of neointimal
hyperplasia are nitric oxide (NO) and prostaglandins. NO
inhibits SMC proliferation and migration through cyclic
guanosine monophosphate–dependent pathways.6,7 In
vivo experimental evidence for an inhibitory function of
NO has been provided by gene transfer studies that dem-
onstrating that intimal hyperplasia is inhibited by overex-
pression of endothelial cell NO synthase (ecNOS)8-10 and
inducible NO synthase (iNOS).11 In addition, neointimal
hyperplasia and constrictive arterial remodeling were in-
creased in studies in mice deficient in iNOS, ecNOS, and115
thase
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conclusion that NOS activity inhibits the response to vas-
cular injury. In contrast, one study reported decreased
intimal hyperplasia in iNOS knockout mice, which suggests
that iNOS might also have the potential to promote intimal
hyperplasia.14 Therefore, despite some controversy, NOS
activity appears to be a likely mechanism for mediation of
endogenous growth inhibitory effects in response to vascu-
lar injury.
The role of cyclooxygenase-1 (COX1) and cyclooxy-
genase-2 (COX2) during restenosis and atherosclerosis in
vivo is even more difficult to define. A recent clinical trial
suggested that use of COX2-selective inhibitors is associ-
ated with increased risk for cardiovascular events.15 In
contrast, animal studies showed a protective effect of
COX1 and COX2 inhibitors in experimental atherosclero-
sis.16,17 After balloon injury of carotid arteries in rats,
which is an experimental model of neointimal hyperplasia
without pronounced inflammation and lipid accumulation,
COX inhibitors had no effect.18,19 These findings are in
contrast to the pronounced anti-proliferative and anti-
migratory effects of vasodilatory prostaglandins such as
prostacyclin and prostaglandin E2 in vitro.
20 Therefore, we
hypothesize that in vivo, during fibroproliferative vessel
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The goal of the present study was to investigate how
simultaneous inhibition of COX1 and COX2, and iNOS,
ecNOS, and nNOS by pharmacologic means affects neoin-
timal hyperplasia in the balloon injury model in rats. For
this purpose, use of specific inhibitors of ecNOS versus
iNOS and COX1 versus COX2 were deliberately not used,
because it was intended to determine the overall effect of
NOS and COX during neointimal hyperplasia. Accord-
ingly, Fischer 344 rats were treated with N-nitro-L-arginine
(L-NA), an inhibitor of ecNOS, iNOS, and nNOS, and
indomethacin, an inhibitor of COX1 and COX2, either
alone or in combination.
METHODS
Animals, surgery, and tissue preparation. Three-
month-old male Fischer 344 rats (Simonsen Laboratories)
received either normal tap water or tap water plus L-NA
(Sigma), an inhibitor of NO synthesis. The water consump-
tion was monitored and the L-NA concentration in the
e (NO) in vessel wall. Arachidonic acid is liberated from
olipase A2 (PLA2). Arachidonic acid is subsequently
by cyclooxygenase-1 and cyclooxygenase-2 (COX1/2)
din H2 (PG H2). PGH2 is the substrate of individual
PGE2, and thromboxane A2 (TXA2). The synthetic
s of simplicity. NO is synthesized from L-arginine by
ide synthases (NOS) via the intermediate NG-hydroxy-
essel diameter, the synthetic smooth muscle cell (SMC)
ws symbolize enhancement; lines with crossbar indicate
h high proliferative, migratory, and synthetic activity.
; PGE-S, prostaglandin E synthase.c oxid
hosph
n) or
aglan
GI2,
eason
ric ox
on v
(arro
wit
JOURNAL OF VASCULAR SURGERY
Volume 40, Number 1 Fischer, Hawkins, and Clowes 117drinking water adjusted to ensure an L-NA dose of 10
mg/kg/d. In a previous study this dose of L-NA inhibited
NO generation and decreased cyclic guanosine monophos-
phate levels in injured arteries.9 In addition, a suspension of
indomethacin in 5% ethanol (0.2 mL) was given by
gavage once a day (1.5 mg/kg/d). The control animals and
the L-NA–treated animals received the same amount of
vehicle (5% ethanol) by gavage. In additional experiments
hydralazine (13 mg/kg/d) was administered continuously
by subcutaneous infusion via an Alzet mini-osmotic pump
(Alza Corp) implanted subcutaneously in the neck of the
animals. The drug treatment was initiated 24 hours before
balloon injury. Balloon injury was performed as described.4
Systolic arterial blood pressure was measured in con-
scious, restrained rats by tail-cuff plethysmography (Norco
Biosystems). The measurement was performed twice be-
fore the drug treatment to obtain the baseline value for
each rat, and subsequently at 3, 7, and 13 days after balloon
injury.
After 14 days the animals were sacrificed, fixed by
perfusion with 10% neutral buffered formalin (pH 7.4) at
100 mm Hg. Two pieces of each carotid artery were em-
bedded in paraffin for histologic analysis. The rats received
50 mg of 5-bromo-2-deoxyuridine (BrdU) subcutane-
ously 24 hours before they were sacrificed. Subsequently,
paraffin-embedded cross sections were used for immuno-
staining and for morphometric measurements, as de-
scribed.21 Because the extent of intimal hyperplasia varied
between independent experiments, data derived from indi-
vidual experiments were subsequently normalized to me-
dial areas (intima-media [i/m] ratio) and presented as
increase of i/m ratio over the respective controls. This
analysis enabled pooling of data from 3 independent exper-
iments.
All surgical procedures were performed according to
the Principles of Laboratory Animal Care and the Guide for
the Care and Use of Laboratory Animals (NIH Publication
No. 86-23, revised 1985), and were approved by the Uni-
versity of Washington, Seattle.
Immunocytochemistry. Rabbit antiserum to the core
protein of human versican was generously provided by Dr
Richard Le Baron (University of Texas at San Antonio),
and was used at 1:100 dilution in phosphate-buffered saline
solution plus 0.1% bovine serum albumin. Sections to be
stained for the proteoglycan core protein of versican were
digested with chondroitin ABC lyase (ICN Biomedicals) at
200 mU/mL in 0.1 mol/L of Tris-acetate, pH 7.3, for 1
hour at 37°C. BrdU incorporation was detected with a
specific monoclonal antibody to BrdU (Boehringer Mann-
heim). BrdU-positive and BrdU-negative nuclei were
counted under a microscope, and the proliferative index
(percent BrdU-positive cells) was calculated.
Measurement of 6-keto-prostaglandin F1. In pre-
liminary experiments we determined whether the dose of
indomethacin (1.5 mg/kg/d) effectively inhibited prosta-
cyclin synthesis. After 3 days of treatment, rats were sacri-
ficed with an overdose of pentobarbital. Subsequently
blood and the thoracic aorta were harvested. Plasma wasobtained by routine centrifugation and used directly for
determination of 6-keto-prostaglandin F1 (6-keto-PGF1)
concentrations, the degradation product of prostacyclin,
with the TiterZyme enzyme immunoassay kit (PerSeptive
Diagnostics). The 6-keto-PGF1 plasma concentration in
indomethacin-treated animals was reduced to 200  15
pg/mL, compared with 1000  212 pg/mL in untreated
animals. In addition, the aorta was chopped into pieces of
approximately equal size, which were subsequently placed
in serum-free tissue culture medium. After 3 initial washes
with serum-free medium, 1 mL of serum-free medium was
added either with or without phorbol-12-myristate-13-
acetate (PMA, 10 mol/L), which induces COX-2 activity
and prostacyclin release.22,23 After 6 hours the medium was
collected and the amount of 6-keto-PGF1 determined.
Subsequently the pieces of the carotid artery were assayed
for protein content, and the release of 6-keto-PGF1 per
milligram of protein was calculated. In control animals, a
3.8-fold  0.3-fold (mean  SD; n  3) stimulation of
6-keto-PGF1 release over unstimulated controls was in-
duced by PMA, which was completely abolished in vessels
of indomethacin-treated animals (1.1-fold 0.2-fold stim-
ulation over controls; n  3). Therefore it was concluded
that 1.5 mg of indomethacin per kilogram per day was an
appropriate dose to inhibit COX activity in the present
experimental system.
Reagents. All reagents and chemicals were purchased
from Sigma, unless otherwise stated.
Statistical analysis. Data are expressed as mean SD.
Statistical analysis was performed with analysis of variance
and Dunnet post hoc test.
RESULTS
Intimal hyperplasia at 14 days after balloon injury
is enhanced by simultaneous treatment with L-NA and
indomethacin. To characterize the neointima 14 days af-
ter injury, 3 independent experiments were performed (Ta-
ble, group 1). Fig 2, A, shows representative cross sections,
and Fig 2, B, shows original data (square millimeters per
cross section) of intimal hyperplasia obtained from 1 of 3
experiments. Fig 3, A, shows the increase over controls of
i/m ratios from the 3 independent experiments. At 2 weeks
after injury the inhibition of NOS by L-NA induced a slight
increase in i/m ratio by a factor of 1.29  0.29 (n  14; P
 .05 vs control). The treatment with indomethacin alone
had no effect on i/m ratio. However, L-NA plus indometh-
acin caused a dramatic further increase in i/m ratio that was
higher than after treatment with L-NA alone (factor of 1.65
 0.53; n 14; P .05 vs L-NA). The use of the i/m ratio
was justified because the medial area of the injured arteries
was not altered by the drug treatment (Fig 3, B) at 14 days.
Furthermore, the medial areas of the contralateral unin-
jured carotid arteries were not changed in any of the groups
at 14 days after injury (data not shown).
With respect to proliferation of neointimal SMCs, in
rats treated with L-NA and with L-NA plus indomethacin
intimal proliferation remained slightly elevated at 14 days
compared with controls (control, 8%  0.7%, n  19;
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Treatment
No. of
rats
Duration of
treatment (d)
Group 1*
Control Vehicle PG 19 15
Indomethacin Indomethacin (1.5 mg/kg/d) PG 6 15
L-NA Vehicle PG L-NA (10 mg/kg/d) PO 14 15
L-NA  indomethacin Indomethacin (1.5 mg/kg/d) PG
L-NA (10 mg/kg/d) PO
14 15
Group 2†
Hydralazine-control Hydralazine (13 mg/kg/d) by osmotic minipump, Vehicle PG 8 15
Hydralazine  L-NA Hydralazine (13 mg/kg/d) by osmotic minipump, Vehicle PG
L-NA (10 mg/kg/d) PO
6 15
Hydralazine  L-NA
 indomethacin
Hydralazine (13 mg/kg/d) by osmotic minipump,
Indomethacin (1.5 mg/kg/d) PG, L-NA (10 mg/kg/d) PO
6 15
Group 3
Control Vehicle PG 5 15
L-NA Vehicle PG L-NA (10 mg/kg/d) PO 6 15
L-NA  indomethacin L-NA (10 mg/kg/d) PO Indomethacin (3.0 mg/kg/d) PG 6 15
L-NA, N-nitro-L-arginine; PG, per gavage; PO, orally.
*Group 1 consisted of three individual experiments (data shown in Figs 2 and 3). Treatment was initiated 24 hours before balloon injury. Indomethacin was
given PG as suspension, and L-NA PO in drinking water.
†Hydralazine was used to lower blood pressure in experimental group 2, and was administered with an Alzet osmotic minipump in addition to L-NA PO andFig 2. Carotid arteries 14 days after balloon injury. A, Cross sections of balloon-injured carotid arteries stained with
hematoxylin-eosin 14 days after injury. a, Untreated control; b, N-nitro-L-arginine (L-NA, 10 mg/kg/d); c,
indomethacin (1.5 mg/kg/d); d, indomethacin (1.5 mg/kg/d) plus L-NA (10 mg/kg/d). Arrows indicate internal
elastic laminas. Original magnification 	40. B, Original measurements of intimal areas per cross section derived from
one representative experiment. Control animals (n  4) received vehicle; additional rats were treated with N-nitro-L-
arginine (L-NA, 10 mg/kg/d; n  5), indomethacin (1.5 mg/kg/d; n  6), or L-NA plus indomethacin (n  5).
*P  .05.indomethacin PG (data shown in Fig 4).
. *P 
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11.5% 3.5%, n 14; P .05 vs control). In addition, the
number of intimal SMCs per cross section was significantly
increased over controls in rats treated with L-NA plus
indomethacin at 14 days (132% 3.7% of control values; n
 14; P  .05), but not in the other groups.
In additional experiments (Table, group 3), a higher
indomethacin dose (3 mg/kg/d) was used in combination
with the same dose of L-NA (10 mg/kg/d). Neointimal
hyperplasia was almost doubled with this treatment (inti-
mal area: controls, 0.054 0.012 mm2, n 5; indometh-
acin plus L-NA, 0.092  0.023 mm2, n  5; P  .05).
The increase in neointimal hyperplasia in response
to treatment with L-NA and indomethacin is blood
pressure–independent. Mean systolic blood pressure was
increased over controls in all 3 groups (Fig 3, C). To
analyze whether this increase in blood pressure might be
involved in the effect on neointimal hyperplasia, blood
pressure was lowered with subcutaneous infusion of hydral-
Fig 3. Pooled data from morphometric analysis of caro
injury. Rats were treated with N-nitro-L-arginine (L-NA
indomethacin. A, Data pooled from 3 independent exper
untreated controls. B, Medial area of injured arteries poo
increase over controls. C, Mean arterial blood pressure. V
indomethacin, n  6, indomethacin plus L-NA, n  14azine (Table, group 2). In response to hydralazine infusion,
blood pressure no longer differed significantly between
treatment groups (controls, 107  17 mm Hg, n  8;
L-NA, 122.5  10 mm Hg, n  6; L-NA plus indometh-
acin, 121  11 mm Hg, n  6; P 
 .05; Fig 4, B).
However, morphometric analysis still revealed a similar
increase in i/m ratio in response to L-NA and to L-NA plus
indomethacin in the hydralazine-treated animals (Fig 4, A),
compared with those without pharmacologic lowering of
blood pressure (compare with Fig 3, A). The increase of
i/m ratio was again strongest in the group receiving L-NA
plus indomethacin. A group of animals receiving indo-
methacin alone plus hydralazine was not included, because
indomethacin alone had no effect on neointimal hyperpla-
sia (Figs 2 and 3).
Another reason to assume that the increase in arterial
blood pressure is not crucial for the observed synergistic
enhancement of neointimal hyperplasia in response to
L-NA and to L-NA plus indomethacin is that blood pres-
teries and arterial blood pressure 14 days after balloon
g/kg/d), indomethacin (1.5 mg/kg/d), or L-NA plus
ts expressed as x-fold increase of intima-media ratio over
rom 3 independent experiments and expressed as x-fold
represent mean SD; controls, n 19; L-NA, n 14;
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indomethacin was elevated to the same extent (Fig 3, C;
control, 126 10.5 mm Hg, n 19; indomethacin, 137
14.5 mm Hg, n  6; L-NA, 161  10.5 mm Hg, n  14;
L-NA plus indomethacin, 162  14 mm Hg, n  14;
values after 13 days of drug treatment.)
Treatment with L-NA plus indomethacin reduces
neointimal cell density. Intimal cell density, expressed as
nuclei per square millimeter, was used as an indicator of the
amount or volume of ECM that accumulates between the
cells (Fig 5, A). Treatment with L-NA plus indomethacin
was associated with an approximately 20% decrease in inti-
mal cell density (control, 10414  2800 nuclei/mm2;
L-NA plus indomethacin, 8062  2200 nuclei/mm2; P 
.05; Fig 5, A). This observation points toward increased
accumulation of ECM after simultaneous inhibition of
NOS and COX. Immunostaining for the proteoglycan
versican was much more pronounced in the luminal part of
the neointima in rats treated with L-NA plus indomethacin
(Fig 5, B). Treatment with L-NA or indomethacin alone
had no effect.
DISCUSSION
After removal of the endothelium during balloon in-
jury, iNOS is strongly upregulated in medial and intimal
SMCs.24-27 iNOS can be detected as early as 1 day after
injury in the medial SMCs, and up to 2 weeks in the intimal
SMCs. Similarly, COX2 is expressed in intimal SMCs after
balloon injury. Beginning as early as 2 hours after injury,
the expression of COX2 remains increased for at least 2
weeks.28-30 Taken together, both iNOS and COX2 are
induced after balloon injury, and are expressed for at least 2
weeks after injury. However, the functional relevance of the
co-expression of these enzymes during neointimal hyper-
plasia has not been investigated.
At 14 days after injury, inhibition of COX1 and COX2
by indomethacin had no effect on SMC proliferation and
intimal hyperplasia, which confirms the results of previous
studies that showed no effect of the COX inhibitors aspirin
and flurbiprofen.18,19 The administration of L-NA, how-
Fig 4. Intimal hyperplasia at 14 days and mean arterial
mg/kg/24 hr of hydralazine in addition to N-nitro-L-arg
mg/kg/d). A, Fold increase of intima-media ratio ove
controls, n  8; L-NA, n  6, indomethacin plus L-NAever, caused an increase in intimal thickening (1.29-fold)
and intimal SMC proliferation. These findings also are in
line with those of previous studies that showed that gene
transfer of ecNOS8-10 or iNOS11 or the administration of
L-arginine31 inhibited neointimal thickening. However,
the most important result of the present study is that
simultaneous inhibition of NOS and COX synergistically
increased neointimal hyperplasia.
The rise in mean arterial blood pressure in the animals
treated with L-NA and with L-NA plus indomethacin must
be considered a potential mechanism that causes enhanced
intimal expansion and SMC proliferation. However, the
increase in pressure (30 mm Hg) did not lead to increased
medial areas in the uninjured contralateral vessels. Further-
more, no difference was detected between blood pressure
in rats treated with L-NA and those treated with L-NA plus
indomethacin, although neointimal hyperplasia was dra-
matically increased in rats treated simultaneously with both
inhibitors. In addition, subcutaneous infusion of hydral-
azine (13 mg/kg/d) was used to reduce blood pressure in
all groups. After hydralazine infusion, blood pressure in
animals treated with L-NA and with L-NA plus indometh-
acin was not significantly different from that in control
animals that received only hydralazine, but treatment with
L-NA plus indomethacin still caused the same increase in
i/m ratio as observed in the experiments without hydral-
azine. These data support the conclusion that NO and
prostanoids have synergistic inhibitory effects on intimal
hyperplasia that are independent of elevation of blood
pressure.
On the basis of the present data, possible mechanisms
responsible for enhanced intimal hyperplasia after treat-
ment with L-NA plus indomethacin include increased pro-
liferation of intimal SMCs, which was found in the L-NA
and the L-NA plus indomethacin groups at 14 days, and
increased accumulation of ECM, which was detected by a
significant decrease in intimal cell density at 14 days after
combined drug treatment. Versican, a large, extracellular
chondroitin sulfate proteoglycan, is induced within the first
pressure in rats receiving subcutaneous infusion of 13
(L-NA, 10 mg/kg/d) or L-NA plus indomethacin (1.5
oon-injured controls. B, Mean arterial blood pressure;
6. *P  .05.blood
inine
r ball
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neointima.32 Versican possesses numerous large chon-
droitin sulfate chains, and binds to hyaluronan.33 This
interaction leads to formation of large, highly hydrated
networks, which contribute substantially to the volume
occupied by the ECM. Furthermore, versican supports
proliferation and migration of vascular SMCs.34 Therefore
versican is thought to promote intimal expansion during
early stages of neointimal hyperplasia. In addition to the rat
model, versican is believed to serve similar functions in
lesions in human beings.32,35 As shown at immunostaining,
the accumulation of versican was increased in the luminal
part of the neointima in animals treated with L-NA plus
indomethacin, which invites the hypothesis that increased
versican accumulation might be causally involved in the
effect of L-NA and indomethacin on neointimal hyperpla-
sia. The observation that NO and prostaglandin derivatives
are involved in the regulation of neointimal ECM accumu-
lation is in line with studies that showed that both NO36-39
and prostaglandins40,41 reduce expression of various ECM
proteins, for example, fibronectin, collagen, and proteogly-
cans, in other experimental models. Whether versican ex-
Fig 5. A, Fourteen days after injury. Controls, n  19
indomethacin plus L-NA, n 14. *P .05, control vs L
carotid arteries by 14 days, immunostaining of versican c
indomethacin (1.5 mg/kg/d); d, indomethacin (1.5 m
above the versican-rich luminal part of the neointima. A
	 40.pression by SMCs is directly repressed by NO and prosta-
noids needs to be addressed in future studies. Based on the
literature and the present findings, it is likely that control of
neointimal SMC proliferation and migration, and inhibi-
tion of ECM accumulation mediate an inhibitory effect of
NO and prostanoids on neointimal hyperplasia. With re-
spect to the pathophysiology of neointimal hyperplasia, these
data suggest that endogenously produced NO and prosta-
noids cooperate to limit the extent of neointimal hyperplasia.
In conclusion, pharmacologic inhibition of NOS and
COX synergistically enhance neointimal hyperplasia. Inas-
much as many pharmacologic interventions modulate the
activity of NOS or COX, possible effects with respect to
vascular remodeling may have to be considered.
We thank Patti Polinsky and Holly Lea (University of
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